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Direct or Coincidental Elimination of
Stable Rotors or Focal Sources May
Explain Successful Atrial Fibrillation Ablation
On-Treatment Analysis of the CONFIRM Trial (Conventional Ablation
for AF With or Without Focal Impulse and Rotor Modulation)
Sanjiv M. Narayan, MD, PHD,*†‡ David E. Krummen, MD,*† Paul Clopton, MS,†
Kalyanam Shivkumar, MD, PHD,‡ John M. Miller, MD§
San Diego and Los Angeles, California; and Indianapolis, Indiana
Objectives This study sought to determine whether ablation of recently described stable atrial fibrillation (AF) sources, ei-
ther directly by Focal Impulse and Rotor Modulation (FIRM) or coincidentally when anatomic ablation passes
through AF sources, may explain long-term freedom from AF.
Background It is unclear why conventional anatomic AF ablation can be effective in some patients yet ineffective in others
with similar profiles.
Methods The CONFIRM (Conventional Ablation for AF With or Without Focal Impulse and Rotor Modulation) trial prospec-
tively revealed stable AF rotors or focal sources in 98 of 101 subjects with AF at 107 consecutive ablation
cases. In 1:2 fashion, subjects received targeted source ablation (FIRM) followed by conventional ablation, or
conventional ablation alone. We determined whether ablation lesions on electroanatomic maps passed through
AF sources on FIRM maps.
Results Subjects who completed follow-up (n  94; 71.2% with persistent AF) showed 2.3  1.1 concurrent AF rotors or
focal sources that lay near pulmonary veins (22.8%), left atrial roof (16.0%), and elsewhere in the left (28.2%)
and right (33.0%) atria. AF sources were ablated directly in 100% of FIRM cases and coincidentally (e.g., left
atrial roof) in 45% of conventional cases (p  0.05). During a median (interquartile range) of 273 days (138 to
636 days) after one procedure, AF was absent in 80.3% of patients if sources were ablated but in only 18.2% of
patients if sources were missed (p  0.001). Freedom from AF was highest if all sources were ablated, interme-
diate if some sources were ablated, and lowest if no sources were ablated (p  0.001).
Conclusions Elimination of stable AF rotors and focal sources may explain freedom from AF after diverse approaches to abla-
tion. Patient-specific AF source distributions are consistent with the reported success of specific anatomic lesion
sets and of widespread ablation. These results support targeting AF sources to reduce unnecessary ablation, and
motivate studies on FIRM-only ablation. (The Dynamics of Human Atrial Fibrillation; NCT01008722) (J Am Coll
Cardiol 2013;62:138–47) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.03.021Atrial fibrillation (AF) is a major cause of morbidity and
mortality, for which pharmacologic approaches for rate (1) or
hythm control (2) remain suboptimal. Catheter ablation is a
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July 9, 2013:138–47 Direct or Coincidental Ablation of AF Rotorsnonpharmacological therapy with the potential to eliminate AF,
yet although it is more effective than medications (3–5), it has had
suboptimal success for paroxysmal (6) and persistent (7,8) AF.
Mechanistic uncertainty for AF may contribute to these
limitations of ablation. When mechanisms are well defined,
such as for Wolff-Parkinson-White syndrome (9) or atrio-
ventricular nodal reentry (10), ablation provides85% to 90%
ne-procedure success. Conversely, the reentry circuits or
ocal sources that sustain AF are undefined after AF has
een triggered by ectopy (from pulmonary veins [PVs] or
lsewhere). It is thus unexplained how paroxysmal or
ersistent AF may be eliminated by ablation that does
5–7,11), but also does not (12–14), isolate the PVs.
We hypothesized that freedom from AF should be higher
f lesions pass through stable rotors or focal sources, mech-
nisms recently shown to sustain AF in the CONFIRM
Conventional Ablation With or Without Focal Impulse
nd Rotor Modulation) trial (15) and independent reports
16,17) than if they do not. These studies used a novel
omputational approach to map stable sources in 97% of
atients with paroxysmal or persistent AF, in whom source
blation (FIRM) improved AF freedom compared with
onventional ablation alone on intention-to-treat analysis
15). However, although sources were seen in patients in
oth limbs of CONFIRM, it is unclear whether conven-
ional ablation was more successful if passed through, rather
han bypassed, AF sources.
We tested our hypothesis by defining the locations of
blation lesions and AF sources in each patient in each limb
f the CONFIRM trial (FIRM-guided and -blinded). We
etermined whether lesions that passed through AF
ources, directly by FIRM-mapping guidance or coinciden-
ally by conventional anatomic ablation, conferred higher
ong-term freedom from AF in a pre-specified on-treatment
nalysis of the CONFIRM trial.
ethods
tudy design and enrollment. CONFIRM (15) prospec-
ively enrolled 92 subjects at 107 consecutive AF ablation
rocedures for standard-of-care indications. Subjects were
21 years of age with AF despite receiving one or more
lass I or III anti-arrhythmic drugs. To study AF sources
nd their response to ablation across a broad spectrum of AF
resentations, we included patients with paroxysmal, per-
istent, and longstanding persistent AF (8) and AF despite
rior conventional ablation. The only exclusion criterion
as an inability or refusal to provide specific written
nformed consent.
Consecutive cases were prospectively mapped and as-
igned in a 2:1 ratio to FIRM-blinded (conventional)
blation alone or, after real-time FIRM mapping had
een developed, to FIRM-guided ablation comprising
argeted source ablation (FIRM) followed by conven-
ional ablation. olectrophysiology study. Elec-
rophysiology study was per-
ormed after patients discontin-
ed antiarrhythmic medications
or 5 half-lives (for amiodarone:
60 days [median: 230 days])
Table 1). Intravenous heparin
as infused to maintain an acti-
ated clotting time 350 s. A
4-pole basket catheter (48- or
0-mm diameter; 4 to 6-mm
lectrode spacing; Constellation,
oston Scientific, Natick, Mas-
achusetts) was advanced trans-septally to map the left
trium in all patients and to map the right atrium in 73
atients (including all FIRM-guided cases).
Figure 1A shows a patient in whom simultaneous biatrial
askets were used (recent studies have used one basket for
oth atria [16,17]). AF was observed in 101 cases (including
IRM-guided cases) (15). When required, AF was induced
rapid pacing: n  26; isoproterenol: n  2) because several
tudies have shown similar frequency (18) and spatial
ctivation (19) for induced versus spontaneous AF. Unipolar
nd bipolar AF electrograms were filtered at 0.05 to 500 Hz
nd exported at 1-kHz sampling frequency.
IRM mapping of AF sources. FIRM mapping for AF
as been described previously (15,19). Briefly, AF electro-
rams were recorded in a wide field of view and analyzed
sing RhythmView (Topera, San Diego, California) to
roduce maps of AF propagation. Figure 1B shows a FIRM
ap of an AF rotor (i.e., red-to-blue, early-meets-late spiral
ave). As shown in Figure 1C, this rotor lay at a lateral right
trial site that would not be ablated conventionally.
AF propagation (FIRM) maps were analyzed intraproce-
urally in FIRM-guided patients to guide ablation, and
ost-procedurally in FIRM-blinded patients. Electrical ro-
ors (Figs. 1B and 2) were defined as sustained clockwise or
ounterclockwise activation around a center of rotation, and
ocal impulses (Fig. 2) were defined by centrifugal activation
rom an origin. Rotors and focal impulses were considered
F sources only if stable in repeated samples over 30 to 120
in (i.e., thousands of cycles), distinct from transient
brillatory activity (20,21). The AF focal source origin or
otor center of rotation was located by its electrode coordi-
ates and “shadowed” digitally within each patient-specific
natomic shell (NavX, St. Jude Medical, Inc., St. Paul,
innesota) at the time of each FIRM map to eliminate
rrors from subsequent possible movement. Each digital
hell was created, in turn, using careful sampling of atrial
nd venous points with reference to (or fused with) pre-
rocedural patient-specific computed tomographic scans
hen available.
blation approach. Radiofrequency energy was delivered
ith a 3.5-mm tip irrigated catheter (Thermocool,
iosense-Webster, Diamond Bar, California) at 25 to 35 W
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiography
FIRM  focal impulse and
rotor modulation
LA  left atrium
PV  pulmonary vein
RA  right atrium
WACA  wide-area
circumferential ablationr, in heart failure subjects, an 8-mm tip catheter (Blazer,
tion; AR
140 Narayan et al. JACC Vol. 62, No. 2, 2013
Direct or Coincidental Ablation of AF Rotors July 9, 2013:138–47Boston Scientific) at 40 to 50 W, target 52oC. Each lesion
was registered digitally on each patient’s digital NavX
anatomy. Ablation in FIRM-guided subjects always com-
menced with FIRM. Energy was applied at adjacent sites
for 15 to 30 s to cover the AF source (rotational center or
focal source origin) (15). The endpoint was AF termination,
coverage of the typical 2-cm2 source area (5-min abla-
tion; 2% to 5% of atrial area [22]) or 10 min of energy
application, whichever came first. If AF terminated, vigor-
ous attempts were made to reinitiate AF. FIRM was
repeated for no more than three sources (30 min permit-
ted [15]), followed by conventional ablation.
Conventional ablation (8), performed after FIRM in
FIRM-guided patients and as sole therapy in FIRM-
blinded patients, comprised wide-area circumferential abla-
tion (WACA) to isolate left and right PV pairs, with
verification of PV entrance block using a circular mapping
Clinical CharacteristicsTable 1 Clinical Characteristics
Characteristic
AF presentation
Paroxysmal
Persistent
Age, yrs
Male/female
Nonwhite race, n (%)
History of AF, months
Left atrial diameter, mm
LVEF, %
CHADS2 score
0 or 1
2 or more
NYHA class
0 or I
II or III
Comorbid conditions
Hypertension
Diabetes
Stroke/TIA
Coronary disease
Hypercholesterolemia
Conventional ablation
Previously failed 1 antiarrhythmic drug
Class I
Sotalol
Dofetilide
Amiodarone
Days since amiodarone discontinuation
Concurrent drug therapy
ACEI/ARB
Beta-adrenoreceptor antagonist
Calcium-channel blocker
Statin
Values are n (%), mean  SD, and median (interquartile range) we
U test, respectively.
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrilla
fraction; TIA  transient ischemic attack.catheter. In persistent AF, a left atrial roof line withconfirmation of block was also performed. Cardioversion
was performed if necessary.
On-treatment analysis: did ablation pass through sources?
Electroanatomic and FIRM maps were analyzed per pa-
tient, blinded to demographics, outcomes, and assignment
to FIRM-guided or conventional ablation limbs. Source
ablation was assigned if 5-mm lesion markers on NavX
(Figs. 1 to 4) lay within 50% of the interelectrode spacing
(on the digital shell) to electrodes recording the rotor core or
focal origin. Two analyses were performed. First, any source
ablation was assigned if 1 source was ablated, and no source
ablation was assigned otherwise. Conventional ablation was left
atrial, so that this analysis could be performed in all patients
(FIRM-blinded and -guided) who all received left atrial FIRM
maps. Second, we measured FIRM dose response by assign-
ing all source ablation (e.g., 3 of 3 concurrent sources),
some source ablation (e.g., 2 of 3 sources ablated), and no
Source Ablation
(n  61)
No Source Ablation
(n  33) p Value
0.63
19 (31.1%) 8 (24.2%)
42 (68.9%) 25 (75.8%)
61.6 8.3 61.0 8.8 0.77
58/3 31/2 1.00
9 (14.8%) 4 (12.1%) 1.00
47 (27–107) 47 (21–110) 0.81
46 7 45 7 0.35
54 13 55 11 0.48
0.08
26 (42.6%) 21 (63.6%)
35 (57.4%) 12 (36.4%)
0.32
52 (85.2%) 31 (93.9%)
9 (14.8%) 2 (6.1%)
50 (82.0%) 23 (69.7%) 0.20
21 (34.4%) 7 (21.1%) 0.24
11 (18.0%) 4 (12.1%) 0.56
26 (42.6%) 5 (15.2%) 0.01
47 (77.0%) 20 (60.6%) 0.10
22 (36.1%) 10 (30.3%) 0.65
21 (34.4%) 12 (36.4%) 1.00
15 (24.6%) 8 (24.2%) 1.00
30 (49.2%) 19 (57.6%) 0.52
13 (21.3%) 5 (15.2%) 0.59
29 (47.5%) 15 (45.5%) 1.00
65 (60–365) 97 (60–365) 0.36
36 (59.0%) 22 (66.7%) 0.51
43 (70.5%) 22 (66.7%) 0.82
15 (24.6%) 9 (27.3%) 0.81
35 (57.4%) 14 (42.2%) 0.20
ated with the Fisher exact test, Student t test, and Mann-Whitney
B  angiotensin II receptor blocker; LVEF  left ventricular ejectionAny
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July 9, 2013:138–47 Direct or Coincidental Ablation of AF Rotorssources, this secondary analysis was performed only in
patients with biatrial FIRM maps. Assignments were
performed independently by 4 of the authors (S.M.N.,
D.E.K., K.S., and J.M.M.), and disputes were resolved
using consensus.
Post-procedure clinical management. Follow-up for ar-
rhythmia recurrence met or exceeded guidelines (23). In the
first 3 months post-ablation, antiarrhythmic medications
were continued and cardioversion performed if indicated,
but neither repeat ablation nor cross-overs were permitted.
Subjects were then evaluated quarterly for up to 24 months.
Arrhythmia recurrence was detected using continuous im-
planted electrocardiographic (ECG) monitors when con-
sent was obtained (Reveal XT, Medtronic, Minneapolis,
Minnesota) after U.S. approval in 2009 (Fig. 1A), or clinical
pacemaker/defibrillator. Remaining subjects received exter-
nal Holter or event monitors each quarter and also at the
time of any symptoms.
Study endpoints. The primary long-term efficacy endpoint
was freedom from AF after the FIRM-mapping procedure,
efined as 1% burden on continuous implanted ECG
onitors (actual burden: 0.1  0.2%, as presented in
ONFIRM [15]), or AF 30 s on intermittent monitors
8). Secondary efficacy measures included freedom from
ll atrial arrhythmias, and outcomes in patients at first
blation. Four patients in the CONFIRM trial were lost
o follow-up (15).
tatistical analysis. Continuous data are represented as
ean  SD or median (interquartile range [IQR]) as appro-
riate. Normality was evaluated using the Kolmogorov-
mirnov test. Comparisons between the two groups were made
ith the Student t test and summarized with mean  SD for
independent samples if normally distributed or, if not
Figure 1 FIRM of AF Sources
(A) Fluoroscopy of bi-atrial 128 electrode wide-field of view mapping in atrial fibrilla
raphy recorder, diagnostic catheter in the coronary sinus, ablation catheter in the
rotor mapping (FIRM) maps show two independent sources: an AF rotor in an unco
atrium: Top, superior vena cava; Left, lateral tricuspid. Left atrium: Top, superior m
(same patient as in B).normally distributed, evaluated using the Mann-WhitneyU test and summarized with median (IQR). Nominal values
are expressed as n (%) and compared using the Fisher exact
test. Associations between continuous variables were evalu-
ated using Spearman correlation. Interobserver agreement
in assigning source ablation (S.M.N., D.E.K., K.S., and
J.M.M.) was measured using the kappa score. Long-term
outcome was assessed and reported after the single FIRM-
map procedure, raw event rates were compared using the
chi-square test, and event-free survival plots were made
using the Kaplan-Meier method and compared using the
log rank test. A probability of 0.05 was considered
statistically significant throughout. Statistical analyses were
completed using SPSS version 19 (Systat Software, Inc.,
Chicago, Illinois).
Results
Procedural AF was observed in 101 patients in the CONFIRM
trial, of whom this on-treatment analysis reports n  94
with identified sources and follow-up. Table 1 describes
this study population.
Characteristics of AF rotors and focal sources. FIRM
mapping revealed 2.3  1.1 concurrent AF sources per
patient (median: 2; IQR: 1 to 3) in diverse biatrial locations.
Figures 1B to 2C show stable AF sources at atrial sites
not conventionally ablated. After FIRM-guided ablation,
these patients remain AF-free at 15, 15, 15, and 14
months, respectively. Figure 3 summarizes source loca-
tions in the CONFIRM trial in patients with paroxysmal
AF (Fig. 3A) and persistent AF (Fig. 3B) patients.
Notably, no sources lay inside PV sleeves, as would have
been indicated by activation emanating from electrodes
AF) (right atrial [RA] oblique projection). An implantable continuous electrocardiog-
ium and esophageal temperature probe are also seen. (B) Focal impulse and
onal lateral RA location and a concurrent left atrial focal source. Orientation right
nnulus. (C) AF rotor in lateral RA on patient-specific electroanatomic shelltion (
left atr
nventi
itral aspanning PV ostia. However, 50.9% of sources lay near
142 Narayan et al. JACC Vol. 62, No. 2, 2013
Direct or Coincidental Ablation of AF Rotors July 9, 2013:138–47the PVs and LA roof in paroxysmal AF, and 33.5% in
persistent AF (p  0.05).
Source-ablated and non–source-ablated groups. Abla-
tion lesions passed through one or more stable AF
sources in 64.9% (61 of 94) of cases, composing 45% (27
of 60) of FIRM-blinded patients and 100% (34 of 34) of
FIRM-guided cases (Table 1). The interobserver kappa
score for assignment of source- versus no-source lesion
Figure 2 AF Sources Remote From Conventional Ablation Sites
(A) AF rotor (clockwise, 3.2 cm2) in inferior left atrium in an 85-year-old with parox
with PAF. (C) AF focal source (1.8 cm2) in anterior left atrium (anterior to typical ro
and are AF-free on implanted cardiac monitoring at 1 year. Orientations for FIRMdelivery was 0.898.Sources comprised rotors in 79.1% and focal impulses in
20.9%; the difference between source-ablated and non–
source-ablated groups was not significant. The ratio of
right-to-left atrial sources trended higher in patients with
no source ablation versus with source ablation (p  0.13)
(Table 2).
Coincidental ablation of AF sources. Figure 4 illustrates
AF sources lying near conventional ablation sites. Figure 4A
AF. (B) AF focal source (2.0 cm2) in mid-posterior left atrium in a 64-year-old
) in a 48-year-old with persistent AF. All cases received FIRM-guided ablation,
as in Figure 1B. Abbreviations as in Figure 1.ysmal
of line
mapsshows an AF rotor septal to the left superior PV ostium in
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July 9, 2013:138–47 Direct or Coincidental Ablation of AF Rotorspersistent AF. Its FIRM lesion area (2.1 cm2) fell naturally
long the subsequent left WACA, indicating that this AF
otor may have been ablated “coincidentally” by conventional
blation alone. Figure 4B shows 2 FIRM sites near the left PVs
ustaining persistent AF, of which the superior FIRM set
2.2 cm2) also lay naturally along the subsequent left WACA.
n this case, the inferior FIRM site (1.9 cm2) may have been
issed by conventional ablation, although with FIRM-
Figure 3 AF Focal Impulse and
Rotor Locations in the CONFIRM Trial
Locations as a percentage of all sources for each atrial fibrillation (AF) type:
(A) paroxysmal and (B) persistent. Focal impulses indicated by stars; rotors,
by circles. CONFIRM  Conventional Ablation for AF With or Without Focal
Impulse and Rotor Modulation; IVC  inferior vena cavae; LAA  left atrial
appendage; LIPV  left inferior pulmonary vein; LSPV  left superior pulmonary
vein; RAA  right atrial appendages; RIPV  right inferior pulmonary vein;
RSPV  right superior pulmonary vein; SVC  inferior, superior venae cavae.uidance it was ablated and joined to the left WACA. sFigure 4C illustrates an AF rotor in persistent AF that
as coincidentally ablated during an empirical LA roof line.
ilateral PV isolation had been performed, with no measur-
ble impact on AF. Shortly after starting the LA roof line,
efore it was completed, AF terminated abruptly to sinus
hythm by ablation at the red dot site. The FIRM map was
enerated after the procedure, and showed a rotor at this
recise site. Each patient remains AF-free on follow-up.
F source ablation and long-term efficacy. Over a me-
ian follow-up of 273 days (IQR: 138 to 636 days), freedom
rom AF was higher in the group in which ablation passed
hrough sources versus no sources (49 of 61 [80.3%] vs. 6/33
18.2%], respectively; p  0.001). Results were unchanged
hen examining only first-ablation cases (33 of 42 [78.6%]
s. 4 of 22 [18.2%]; p  0.001). Fig. 5A shows the
aplan-Meier plot. Freedom from AF was similar whether
ources were ablated directly (FIRM-guided) or coinciden-
ally (FIRM-blinded) (Fig. 5B). Freedom from any atrial
achyarrhythmias was also higher when ablation did versus
id not pass through sources (43 of 61 [70.5%] vs. 5 of 33
15.2%]; p  0.001). In FIRM-guided patients, these in-
luded one case of cavotricuspid isthmus–dependent flutter
nd two cases of left atrial tachycardia; in FIRM-blinded
atients, this included four cases of left atrial tachycardia.
inally, Figure 5C presents a Kaplan-Meier plot showing
hat freedom from AF was highest if all sources were ablated
29 of 33 [87.9%]), intermediate if some sources were
blated (8 of 12 [66.7%]), and lowest if no sources were
blated (4 of 4 [16.7%]).
Overall, 44% of patients had implantable ECG monitors
88.2% FIRM-guided, 26.1% FIRM-blinded), comprising
3 of 61 (54.1%) in the source-ablated group versus 10 of 33
30.3%) in the non–source-ablated group (p  0.03).
iscussion
he major finding of this study is that ablation of stable AF
ources at diverse patient-specific locations provides a po-
ential unifying explanation of why diverse AF lesion sets
liminate AF on follow-up in some patients but not others.
table AF sources occurred in 97% of patients in the
ONFIRM trial, lying both near to and remote from
onventional lesion sets, including in the right atrium.
otably, biatrial source distributions were consistent with
he single-procedure success for PV-focused ablation in par-
xysmal AF, with the higher success achieved when extensive
esions were delivered, and a 70% success ceiling for persis-
ent AF after multiple left atrial procedures (because 30% of
ources were right atrial). These data further support patient-
ailored ablation, suggesting that ablation of stable AF sources
ay improve outcomes and reduce the extent of ablation, and
otivating future studies on FIRM-only ablation.
table AF sources. Although direct evidence for stable
ources for human AF is recent (15,16), a large indirect
ody of literature exists showing that localized ablation at
ites of high dominant frequency, fractionated electrograms,
144 Narayan et al. JACC Vol. 62, No. 2, 2013
Direct or Coincidental Ablation of AF Rotors July 9, 2013:138–47and other “substrates” may eliminate AF (24–26); that
persistent AF can terminate at the first ablation steps (25);
and that AF patients show consistent gradients in frequency
(27,28) and organization (29,30) over time.
Human AF rotors show many characteristics similar to
Figure 4 AF Rotors Near Conventional Ablation Targets
(A) Left atrial AF rotor successfully ablated by FIRM, that was then incorporated into l
ablated by FIRM. The superior rotor was incorporated into the left wide-area circumfere
Left atrial roof AF rotor ablated coincidentally by empirical roof ablation in a man with
revealed an AF rotor at the precise point of AF termination. All patients are AF-free. FIRthose of rotors in some animal models (31–34), includinglimited precession (22,35) in conserved areas that define
FIRM lesion sets. The role of stable sources in sustaining
human AF is shown by the ability of FIRM ablation alone
(35,36) to terminate and render AF noninducible
(16,17,22), and by higher freedom from AF in patients
e-area circumferential PV ablation. (B) Two left atrial AF rotors, each successfully
ulmonary vein ablation, while the inferior rotor (isochrones shown) was nearby. (C)
ent AF. AF terminated at the point indicated by a red dot. Offline FIRM analysis later
al orientations are as in Figure 1B. Abbreviations as in Figure 1.eft wid
ntial p
persist
M atrireceiving FIRM-guided versus conventional ablation (82.4
e Stude
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July 9, 2013:138–47 Direct or Coincidental Ablation of AF Rotorsvs. 44.9% in the CONFIRM trial) (15). Other recent
reports have used contact mapping to reveal stable human
AF rotors by Shannon entropy (37), wavelet similarity (38),
Results of FIRM MappingTable 2 Results of FIRM Mapping
Characteristic Any Source Abl
No. concurrent sources per patient 2.3
Atrial sources
Left 107
Right 46
Left atrial sources
Rotors vs. focal
Rotors 73
Focal sources 34
Near pulmonary veins 37/153
Left atrial roof 28/153
Right atrial sources
Rotors vs. focal
Rotors 42
Focal sources 4
Lateral/posterior vs. medial/septal
Lateral/posterior 34/153
Medial/septal 12/153
Values are mean  SD, n (%), or n/N (%) and were compared with th
Figure 5 Cumulative Freedom From AF
Based on (A) whether ablation did (blue) or did not (red) pass through AF sources
Direct (FIRM-guided, blue) or coincidental (FIRM-blinded, red) source ablation. (C)
bi-atrial baskets. The p values reflect the complete follow-up periods. Abbreviationand isochronal (39) analyses. Collectively, these studies
contradict earlier reports that human AF rotors did not exist
(20) or were not stable (21).
n  61) No Source Ablation (n  33) p Value
1.8 0.6 0.02
0.13
) 31 (58.5%)
) 22 (41.5%)
0.03
) 27 (50.9%)
) 4 (7.5%)
) 10/53 (18.9%) 0.28
) 5/53 (9.4%) 0.08
1.00
) 21 (39.6%)
1 (1.9%)
0.77
) 15/53 (28.3%)
7/53 (13.2%)
nt t test and the Fisher exact test, respectively.
re population (solid lines) and first ablation patients only (dashed lines). (B)
tion of all (green), some (yellow) or no (red) stable AF sources, in patients with
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Direct or Coincidental Ablation of AF Rotors July 9, 2013:138–47The CONFIRM trial (15) and a preliminary 12-center
experience in 200 patients (17) suggest that AF freedom
may be substantially improved with FIRM-guided ablation
compared with conventional ablation. Ongoing studies are
investigating why coincidental source ablation terminates
AF less often than does direct FIRM ablation (15). The
most likely explanation is that FIRM ablation targets all of
the approximately 2 or 3 concurrent rotors or focal sources
(15), whereas this finding is inconsistent with conventional
ablation. Elimination of all sources (Fig. 5C) was actually
more effective than reported in the CONFIRM trial by
intention-to-treat FIRM-guided ablation (15), which in
some patients was not completed at all sources. Elimination
of all sources (Fig. 5C) was more effective than was
elimination of some or none, whereas ablation of some
sources yielded similar results to those reported with con-
ventional ablation (3–5).
Patient-specific distributions of stable AF sources. We
show that stable AF sources lie in patient-specific locations
with 40% to 50% near PVs and left atrial roof, and 20%
o 30% in right atrium. AF source locations were more
idely distributed for persistent than paroxysmal AF.
AF source distributions may reflect fiber architecture
40), fibrosis or scar (41), electrical remodeling (42), or
ltered innervation (43). The precise determinants of AF
ource location await definition, which will require detailed
ranslational studies in model systems (32,34) that recapit-
late human AF. However, the similar source numbers and
IRM-ablation success in patients with and without prior
blation (15) argue that FIRM-identified sources are not
reated by prior lesions and are thus distinct from those in
tudies of ablation line gaps (44).
limination of stable AF sources as a possible explanation
f AF freedom after diverse ablation strategies. It is clear
hat AF can be triggered by ectopic beats from the PVs.
owever, although PV-isolation strategies can eliminate
riggers acutely, it is often difficult to achieve robust PV
solation and additional triggers may lie at undefined sites
utside the PVs (3–6,8).
The present study provides an alternative potential expla-
ation of why ablation treats AF in some patients and not
thers. Elimination of AF sources may explain why WACA
s more effective than is ostial PV isolation (45); why AF
ay not recur in patients whose PVs have reconnected (46);
hy non–PV-encircling lines (47) or fractionated electro-
ram ablation (12) may be effective; and, potentially, why
blation success correlates with the extent of ablated tissue
25) in persistent AF.
tudy limitations. The CONFIRM study was limited by
ts nonrandomized design, although subjects were enrolled,
apped, and treated prospectively. Its strengths included an
ctive-control group (conventional ablation) (rather than
ontrols receiving previously ineffective drugs, as in prior
tudies), and the use of implanted monitors in 88% of
IRM-guided patients. We accept that the lower use ofmplanted monitors in patients receiving conventional ab-ation (and in prior AF trials) reduces the accuracy of
ollow-up by potentially missing intermittent arrhythmia
ecurrences. Future studies may improve on current defini-
ions of source ablation by using contact force-sensing and/or
agnetic resonance imaging to ensure and verify effective
blation at each site. The relatively small numbers of at-risk
atients at longer follow-up periods is also a limitation.
ulticenter studies will address the limitations introduced
y this predominantly male Veterans Affairs population and
ill test the benefits of FIRM-guided ablation in a much
arger population.
onclusions
n this on-treatment analysis of data from the CONFIRM
rial, patients in whom ablation lesions passed through
table AF sources enjoyed 80.3% freedom from AF, while
atients in whom ablation missed all sources had an 18.2%
reedom from AF. Sources lay in widespread biatrial loca-
ions, providing a potential explanation for the success of
iverse anatomically designed lesion sets. These data further
upport FIRM ablation at patient-specific stable AF sources
nd motivate studies on FIRM-only ablation.
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